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Introduction
COVID-19 pneumonitis has become a predominant 
respiratory diagnosis in the ED. Consequently, other 
disease processes can be overlooked- especially in 
younger patients- including E-cigarette or Vaping Product 
Use-Associated Lung Injury (EVALI).  A case of a patient 
with EVALI mistaken for COVID-19 is presented
Case Description
A 16-year-old boy with PMH of asthma presented to the ED with dyspnea and cough 
of abrupt onset 24 hours prior to ED visit.  He had been using his home albuterol 
without improvement. There were no known sick contacts, but patient was employed 
at a chain restaurant. Notable VS included: HR 116, RR 32, RA pulse ox 90% (99% 
on HFNC 40L 50%), T 100.2˚F. CXR demonstrated bilateral pulmonary infiltrates 
concerning for multifocal pneumonia and possible evolving ARDS. Chest CT scan 
(Figure 1) revealed: “Diffuse bilateral ground glass opacities. Considerations include 
viral and atypical pneumonia, including COVID 19 pneumonitis”. Notable blood work 
included: WBC 19.4 thou/cm (3.8-10.4 thou/cm), Troponin I 0.27 ng/mL (<0.03 ng/ml). 
Both urine drug screen of abuse and serum LC/MS detected THC. Patient was 
admitted to PICU with presumptive diagnosis of COVID-19 infection. On HD 1 patient 
was transitioned to BiPAP for worsening tachypnea.  Blood culture, urine legionella, 
and respiratory viral panel (including COVID-19) returned negative. Respiratory viral 
panel was repeated and again returned negative.  Upon further inquiry, patient 
reported vaping the day his symptoms began and smoking cannabis regularly. 
Treatment remained supportive with supplemental oxygen and intermittent albuterol/
ipratropium nebulization. Patient was weaned from oxygen by HD 5 and discharged 
in stable condition on HD 6. 
Discussion
EVALI is defined as recent vaping use with development 
of pulmonary infiltrates on chest imaging in the absence 
of another identifiable cause. Although EVALI is 
associated with vape liquid containing THC and vitamin 
E acetate, no single agent has been definitively 
implicated.  Typically, EVALI is associated with 
counterfeit or user filled cartridges. However, this 
patient reported a single use vape pen purchased 
from a convenience store (Figure 2). EVALI 
treatment is primarily supportive with 
supplemental oxygen, bronchodilators, 
steroids, and vaping cessation. 
Conclusion
Despite COVID-19, it is imperative to obtain a detailed 
social history and to maintain a broad differential in 
patients with acute respiratory complaints.
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